Full Library

Chimeric antigen receptors (CARs) are recombinant receptors for antigens that redirect the specificity and function of T lymphocytes or other immune cells in a single molecule. The concept of using CARs in cancer immunotherapy is that CARs, which are programmed to target tumor-associated antigens, can be replicated rapidly and homogeneously. Direct infusion of these armed tumor-targeting T-cells bypass the barriers and kinetics of active immunization. Unlike general passive immunization using a direct antibody, CAR-modified T-cells with supraphysiologic activities work as an active medication, interacting with tumor-associated antigens, which results in both immediate and long-term effects of anti-neoplasm.

PMID: 30725979